Gene-specific cancer treatment is common, but there are still some kinks

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Elaine Mardis and her colleagues first encountered 39-year-old Lucy (not her real name) in 2010 at the Genome Institute at Washington University in St Louis, Missouri. Lucy had been referred there after a confusing leukaemia diagnosis. Her doctors thought she had a subtype of the disease called acute promyelocytic leukaemia (APL) — one of the most treatable forms.

Mardis, co-director of the Genome Institute, is involved in a university initiative to use whole-genome sequencing and other analyses to launch precision attacks against difficult cancers.

Researchers have learned enough about cancer to know that the way it has been tackled for decades — with cocktails of chemotherapeutic drugs that indiscriminately hit populations of rapidly growing cells — is effective only up to a point. They believe that if they can find the key genetic mutations that drive a particular cancer’s growth, they will be able to target the tumour more selectively and with fewer toxic side effects. But they don’t yet know enough about which genetic mutations drive a given cancer, let alone how to interrupt the aberrant cellular pathways that result.

Read the full, original story: Therapy: This time it’s personal

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend